Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC

Summary

The goal of this clinical trial is to investigate the efficacy, safety and tolerability of PD-1/CTLA-4 inhibitor (Cadonilimab) combination with chemotherapy as first-line treatment for PD-L1 negative advanced non small cell lung cancer patients. And also explore the potential biomarkers for predicting the efficacy of PD-1/CTLA-4 inhibitor for advanced non small cell lung cancer.

Timeline

Start

2023-07-04

Primary completion

2024-09-04

Completion

2025-09-04

Drugs

Indications